{name}
{subtitle}
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
city
~9 mi. (Genova, Italy, +383 more cities)
facility
Ente Ospedaliero Ospedali Galliera, +1 more facility
biomarker
ER Negative, +2 more biomarkers
drug
atezolizumab, +4 more drugs
drug type
chemotherapy, +1 more type
Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH
city
~9 mi. (Padova, Italy, +122 more cities)
facility
Istituto Oncologico Veneto IRCCS (IOV)
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~9 mi. (Padova, Italy, +93 more cities)
facility
Istituto Oncologico Veneto IRCCS-Oncologia Medica 1 ( Site 0600)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
city
~9 mi. (Genova, Italy, +262 more cities)
facility
A.O. Universitaria S. Martino Di Genova
biomarker
ER Positive, +1 more biomarker
drug
giredestrant, +2 more drugs
drug type
hormone therapy, +1 more type
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
city
~9 mi. (Padova, Italy, +260 more cities)
facility
IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda
biomarker
ERBB2 Amplification, +1 more biomarker
drug type
immunotherapy, +1 more type
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
city
~9 mi. (Genova, Italy, +115 more cities)
facility
Ospedale Policlinico San Martino; Ist. di Ricovero e Cura a Carattere Scientifico per l'Oncologia
biomarker
ERBB2 Amplification, +7 more biomarkers
drug type
immunotherapy, +1 more type
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
city
~9 mi. (Padova, Italy, +81 more cities)
facility
IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda
drug
atezolizumab, +2 more drugs
drug type
immunotherapy, +1 more type
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
city
~9 mi. (Padova, Italy, +179 more cities)
facility
Istituto Oncologico Veneto IRCCS
drug
atezolizumab, +1 more drug
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
city
~9 mi. (Genova, Italy, +130 more cities)
facility
Azienda Ospedaliero Universitaria San Martino
biomarker
ER Negative, +2 more biomarkers
drug
atezolizumab, +3 more drugs
drug type
chemotherapy, +1 more type